title: Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture. Phase I trial of 14-day continuous ambulatory infusion.
abstract: The compatibility and stability at room temperature for up to 7 days of a three-drug admixture of cyclophosphamide, methotrexate, and 5-fluorouracil (5-FU) (CMF) was established permitting the practical delivery of the combination as an infusion in an ambulatory setting. Fourteen patients received 20 courses of CMF administered on a continuous infusion schedule for 14 days of a 28-day cycle. The dose rates were fixed for 5-FU (300 mg/M2/day) and methotrexate (0.75 mg/M2/day). The cyclophosphamide dose was escalated from 25 to 50, 75, and 100 mg/M2/d. Leukopenia and thrombocytopenia were observed in two of five patients receiving the maximal dose of cyclophosphamide. No other toxicities were observed including alopecia, stomatitis or liver function abnormalities. This Phase I trial suggests that the cumulative doses of cyclophosphamide, methotrexate, and 5-FU are comparable to the maximum doses delivered as single agent infusions. Furthermore, when the infusion CMF is compared to the "standard" bolus schedule for CMF, the infusion schedule delivers 116%, 8%, and 350% of the respective three component drugs (cyclophosphamide, methotrexate, and 5-FU).
authors.affiliation: Cancer Center, Medical Center of Boston, MA 02120.
authors.forename: J
authors.initials: J
authors.lastname: Lokich
authors.forename: M
authors.initials: M
authors.lastname: Bern
authors.forename: N
authors.initials: N
authors.lastname: Anderson
authors.forename: S
authors.initials: S
authors.lastname: Wallach
authors.forename: C
authors.initials: C
authors.lastname: Moore
authors.forename: K
authors.initials: K
authors.lastname: Beauchamp
authors.forename: D
authors.initials: D
authors.lastname: Williams
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004341:Drug Evaluation; D004355:Drug Stability; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008727:Methotrexate / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D004338:Drug Combinations; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate